The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Soft tissue sarcomas (STS) are rare, malignant tumours with a generally poor prognosis. Our aim was to explore the potential of cell free DNA (cfDNA) and circulating tumour DNA (ctDNA) analysis to track non-metastatic STS patients undergoing attempted curative treatment. The analysed cohort (n = 29) contained multiple STS subtypes including myxofibrosarcomas, undifferentiated pleomorphic sarcomas, leiomyosarcomas, and dedifferentiated liposarcomas amongst others. Perioperative cfDNA levels trended towards being elevated in patients (p = 0.07), although did not correlate with tumour size, grade, recurrence or subtype, suggesting a limited diagnostic or prognostic role. To characterise ctDNA, an amplicon panel covering three genes commonly mutated in STSs was first trialled on serial plasma collected from nine patients throughout follow-up. This approach only identified ctDNA in 2.5% (one in 40) of the analysed samples. Next custom-designed droplet digital PCR assays and Ion AmpliSeq™ panels were developed to track single nucleotide variants identified in patients’ STSs by whole exome sequencing (1–6 per patient). These approaches identified ctDNA in 17% of patients. Although ctDNA was identified before radiologically detectable recurrence in two cases, the absence of demonstrable ctDNA in 83% of cases highlights the need for much work before circulating nucleic acids can become a useful means to track STS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Demoret, B., Gregg, J., Liebner, D. A., Tinoco, G., Lenobel, S., & Chen, J. L. (2019) · Cancers · doi:10.3390/cancers11121829 · Cited by 18 · cited 2×
“We show that targeted sequencing of genes commonly mutated in STSs has little value as a screening tool or longitudinal characterisation of ctDNA in patients with non-metastatic primary STS (consistent with a previous study on metastatic STS [19]).”
Background
Cited by
Seidel, M. G., Kashofer, K., Moser, T., Thueringer, A., Liegl-Atzwanger, B., Leithner, A., Szkandera, J., Benesch, M., El-Heliebi, A., & Heitzer, E. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.926405 · Cited by 24
Smolle, M. A., Seidel, M. G., Kashofer, K., Liegl-Atzwanger, B., Sadoghi, P., Müller, D. A., & Leithner, A. (2025) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-024-05711-w · Cited by 16
Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances
Aiyer, S., Kim, T.-H., Collier, K., Pollock, R., Verschraegen, C., Stover, D. G., & Tinoco, G. (2025) · Cancers · doi:10.3390/cancers17061040 · Cited by 11
“Most STSs are in this group [3,5].”
Alabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026) · Cells · doi:10.3390/cells15141271
Metadata
- Authors
- Eastley, N., Sommer, A., Ottolini, B., Neumann, R., Luo, J.-L., Hastings, R. K., McCulloch, T., Esler, C. P., Shaw, J. A., Ashford, R. U., & Royle, N. J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-24
- Volume
- 21
- Issue
- 12
- Pages
- 4483
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3037977609
- Cited by
- 17
- References
- 1
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. https://app.cochat.ai/papers/10.3390/ijms21124483
- The paper
- Eastley, N., Sommer, A., Ottolini, B., Neumann, R., Luo, J.-L., Hastings, R. K., McCulloch, T., Esler, C. P., Shaw, J. A., Ashford, R. U., & Royle, N. J. (2020). The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21124483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.